SHANGHAI, Aug. 17, 2026 /PRNewswire/ — Dingdong (Cayman) Limited (“Dingdong” or the “Company”) (NYSE: DDL), a leading fresh grocery e-commerce company in China, with advanced supply chain capabilities, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2026, before U.S. markets open on August 20, 2026.

About Dingdong (Cayman) Limited

Dingdong is the leading fresh grocery e-commerce company in mainland China, with sustainable long-term growth. The Company directly provides users and households with fresh groceries, prepared food, and other food products through delivering a convenient and excellent shopping experience supported by an extensive self-operated frontline fulfillment grid. Leveraging its deep insights into consumers’ evolving needs and its strong food innovation capabilities, Dingdong has successfully launched a series of private label products spanning a variety of food categories. Many of Dingdong’s private label products are produced at its own production plants, allowing it to more efficiently produce and offer safe and high-quality food products. Dingdong aims to be the first choice for fresh and food shopping.

For more information, please visit: https://ir.100.me.

SYDNEY, Aug. 17, 2026 /PRNewswire/ — The rate of unintended pregnancies continues to soar across Asia Pacific each year, comprising 47% of all pregnancies in the region, and underscoring persistent gaps in access to contraception, counselling and care services. 

As a region of extraordinary diversity, health systems range from highly advanced to chronically under-resourced, with differing funding models, policy frameworks and service availability between countries. Yet, despite advances in recent years, the scale and persistence of unmet need in women’s reproductive health is a reality shared across all. 

Access to modern contraception is about ensuring that every woman and girl can exercise her right to make informed decisions about her body, her health and her future, with voluntary, rights-based family planning remaining one of the most effective investments in women’s health, education and economic participation.

Yet across Asia Pacific, where over 8 million pregnancies happen each year, over half are unintended, leading to a significant number of abortions or unwanted births. This reflects the reality that 140 million women in the region are still without access to family planning, according to the UNFPA. 

The paradox is that many countries in the region are simultaneously facing declining fertility, with rates falling from around five or more children per woman in 1970 towards roughly 2.1 today, causing a shift in demographic realities across the region.

These trends reinforce the need for policies that support individuals and couples to achieve their reproductive intentions rather than enforcing and implementing pronatalist policies. 

But one thing is clear: these challenges are interconnected and systemic and cannot be solved by any single organization acting alone. 

Building access through partnership

Organon was established in 2021 with a commitment to listen and act on issues that affect the health of women. Over the past five years, the company has worked with organizations across Asia Pacific, including governments, NGOs, multilateral agencies and the private sector, to expand access to women’s reproductive health services. This includes initiatives such as Organon’s Her Health Grants, which support community-based partners working to address persistent gaps in women’s health through locally tailored solutions. Progress has been made, but it has not come through scale alone. It has come through partnerships built on trust, shared objectives, collaboration, and deep local understanding. 

Organon is proud to partner with Family Planning 2030 (FP2030) in a global partnership focused on expanding access to voluntary, rights-based services, to advance the Made Possible by Family Planning campaign, a global effort to unlock the transformative impact of reproductive health access. Together, we are mobilizing private-sector leadership through a series of high-impact convenings designed to catalyze investment, strengthen partnerships, and elevate family planning as a driver of economic growth and gender equity.

Our collaboration brings together business leaders, policymakers, youth advocates, and civil society to accelerate progress toward shared goals. By leveraging FP2030’s convening power and Organon’s commitment to women’s health, the partnership aims to unlock innovative financing, amplify regional dialogue, and ensure sustained momentum for rights-based family planning.

At a time when global funding faces significant challenges, this joint effort underscores the critical role of the private sector in safeguarding access to reproductive health and empowering women and families to shape their futures.

For FP2030 and its partners, it has meant bringing together governments, donors, community organisations and industry to align priorities, mobilize commitments, and accelerate country-led progress on family planning and reproductive health. 

Crucially, the most effective partnerships are grounded in a clear understanding of government policy priorities and national health ambitions. Sustainable progress depends on aligning stakeholders around national health priorities while leveraging the complementary strengths of governments, civil society, multilaterals and the private sector. 

The results of this collaborative approach are clear. All FP2030 commitment countries in the Asia Pacific region increased their number of modern contraceptive users between 2020 and 2024. In the same period, all but one country reduced unmet need for family planning among married women aged 15–49.

Together, these experiences reinforce a simple but important truth: partnerships that succeed are not transactional—they are structured collaborations that recognize the interdependence of supply, education, provider capability and policy.

The role of regional platforms

Platforms such as FP2030 also play a critical role in creating a cross-border architecture. In the Asia-Pacific region, eleven governments have made national FP2030 commitments, several of them within the last two years, which, in the context of declining fertility, sends a strong signal that family planning remains essential for advancing gender equality, improving health outcomes, and supporting sustainable development. By convening governments, NGOs, multilaterals and the private sector, FP2030 is helping to align priorities, mobilize resources, create opportunities for cross-country learning and scale what works across countries. 

In Asia Pacific, this model is already taking shape. Partnerships with NGOs, collaboration with multilateral agencies such as UNFPA, and direct engagement with healthcare providers and communities are helping to expand equitable access where unmet need is greatest. At the same time, digital health solutions are increasingly enabling these efforts to reach further and scale more effectively.

A call to act and to partner differently

The women’s health challenges facing Asia Pacific – from unintended pregnancy to shifting fertility patterns to persistent gaps in family planning services – are deeply interconnected.

They will not be addressed through incremental progress or isolated interventions, instead requiring a fundamental shift in how the sector approaches collaboration.

Whether through decentralized global platforms like FP2030 or local delivery partnerships, the path forward depends on moving beyond fragmented efforts toward coordinated, sustained and purpose-driven collaboration.

Across Asia Pacific, governments, industry, community organisations and multilateral organisations are increasingly aligning behind shared goals to address complex challenges. Strengthened collaboration, coordinated action and a clear understanding of policy priorities will be critical to delivering sustainable outcomes in reproductive health for women. 

Authors
Andreas Daugaard Jorgensen, Managing Director, Organon Asia Pacific
Sumita Banerjee, Managing Director, Family Planning 2030 (FP2030) Asia – Pacific

About Organon

Organon is a global healthcare company with a focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialise their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,300 employees with headquarters located in Jersey City, New Jersey, United States of America.

© (2026) Organon group of companies. All rights reserved. Organon and the Organon logo are trademarks of the Organon group of companies.

Organon ANZ, Level 5, 66 King St, Sydney, NSW 2000. First issued August 2026. For more information, visit www.organon.com/australia or connect with us on LinkedIn at @OrganonANZ.

• Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
• Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
• The collaboration further expands the parties’ 2025 oncology biosimilars partnership

SHANGHAI, Aug. 17, 2026 /PRNewswire/ — On August 17, 2026, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into a strategic collaboration with Sandoz (SIX: SDZ; OTCQX: SDZNY), a global leader in generics and biosimilars, covering up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components developed by Henlius. The parties have also signed collaboration terms for an initial three agreed products and an option for one additional asset.

In April 2025, the two companies entered into an exclusive commercialization partnership for HLX13, Henlius’ proposed ipilimumab biosimilar, across 46 countries and regions including Europe and the United States. This new agreement further deepens the existing oncology biosimilars collaboration between the two parties.

Under the strategic collaboration agreement, Henlius will grant Sandoz exclusive rights for registration and commercialization outside China for up to 10 partnered products worldwide. Most of the partnered products are currently at early stages of development, and the two parties will collaborate closely from the early stages of project development. Based on a multi-product portfolio framework, the collaboration will cover key stages across the product lifecycle, including product development, regulatory submissions, manufacturing, launch, commercialization and lifecycle management.

Henlius will leverage its integrated biologics platform to undertake the development, manufacturing and supply of the partnered products, thereby accelerating the development and translation of early-stage molecules. Sandoz has a diversified portfolio of approximately 1,300 medicines, a business presence in around 100 countries and reaches over 1 billion patients worldwide. It has established a strong track record in product registration, market access, launch and commercialization. Leveraging its extensive global footprint, deep localized operating capabilities and market-validated commercialization system, Sandoz will incorporate ex-China market insights and commercial perspectives into product development and registration strategies at an early stage, driving the efficient execution of the partnered products in global markets. Through deep synergies across the entire product lifecycle, the two parties will continue to unlock the global commercial value of the partnered products.

The initial assets covered under the agreement include HLX05-N, a proposed cetuximab biosimilar; HLX16, a proposed evolocumab biosimilar; and a proposed belimumab biosimilar. In addition, Sandoz has obtained an option for HLXTE-HAase1001, a recombinant human hyaluronidase. Based on these arrangements, Sandoz will pay Henlius an upfront payment, relevant milestone payments and a non-refundable option fee totaling up to US$322 million. In 2026, the total invoiced amount expected for Henlius is up to US$100.5 million.

For HLX05-N, the exclusive collaboration territory covers the United States, Canada, the European Union and certain other European countries including the United Kingdom and Switzerland, Japan, Australia and New Zealand, while semi-exclusive rights apply in certain countries and regions in Asia, as well as other markets. For HLX16 and the proposed belimumab biosimilar, the exclusive collaboration territory covers all markets worldwide outside China.

This collaboration represents an important part of Henlius’ globalization strategy. It not only demonstrates the company’s comprehensive strengths in biologics R&D, quality systems, international registration, large-scale manufacturing and global supply, but also further validates the global value of its biosimilars platform. Henlius has established a diversified pipeline spanning biosimilars and innovative biologics, with multiple self-developed biologic products approved in China, the EU, the United States and other global markets.

By partnering with leading global pharmaceutical companies, Henlius continues to expand product access to more countries and regions and accelerate the global commercialization of more biologics. At the same time, the company is continuing to build its own ex-China commercialization capabilities and, based on the market potential, competitive landscape and commercialization needs of different products, is flexibly adopting a combination of independent advancement and strategic partnerships to bring products to global markets through diversified pathways and further unlock the value of its R&D, manufacturing and global supply platforms.

About HLX05-N

HLX05-N is a cetuximab injection biosimilar independently developed by Henlius, intended for the treatment of metastatic colorectal cancer and head and neck squamous cell carcinoma. In July 2026, the first patient has been dosed in a phase 1 clinical study of cetuximab injection biosimilar HLX05-N independently developed by Henlius in patients with metastatic colorectal cancer (mCRC) in China. According to the statistics released by IQVIA MIDAS™ (IQVIA is a global provider of professional information and strategic consulting services in the pharmaceutical and healthcare industry), the sales revenues of cetuximab injection globally amounted to approximately USD1.696 billion in 2025.

About HLX16

HLX16 is an evolocumab biosimilar independently developed by Henlius, intended for the treatment of primary hypercholesterolemia (including heterozygous familial and non-familial types). Currently, this product is in the preclinical research stage. According to the statistics released by IQVIA MIDAS™, the sales revenues of evolocumab injection globally amounted to approximately USD6.602 billion in 2025.

About the proposed belimumab biosimilar

Belimumab biosimilar, independently developed by Henlius, is intended for the treatment of systemic lupus erythematosus and lupus nephritis. Currently, this product is in the preclinical research stage. According to the statistics released by IQVIA MIDAS™, the sales revenues of belimumab injection globally amounted to approximately USD2.475 billion in 2025.

About HLXTE-HAase1001

HLXTE-HAase1001 is a recombinant human hyaluronidase independently developed by Henlius, intended to transform time-consuming intravenous infusion into rapid subcutaneous injection, thereby significantly shortening administration time and improving patient experience. Currently, this product is in the process development stage.

About Henlius

Shanghai Henlius Biotech, Inc. (2696.HK) is a global, innovation-driven biopharmaceutical company committed to delivering high-quality, affordable biologic therapies to patients worldwide. The Company focuses on major disease areas including oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, Henlius has established an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, manufacturing, and commercialisation. The Company employs nearly 4,000 people globally and operates across multiple regions, including China, the United States, and Japan. Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation, Henlius is steadily advancing into its “Globalisation 2.0” phase, building a scalable and sustainable global growth model. Up to date, Henlius has achieved regulatory approvals for 10 products across over 60 countries and regions worldwide, including eight approvals in China. The Company has also reached multiple milestones in major biopharmaceutical markets, with four products approved by the U.S. Food and Drug Administration (FDA) and five products approved by the European Commission (EC), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.

Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other regions. Its innovation platforms span immune checkpoint inhibitors, immune cell engager technologies (including multispecific T cell engagers), antibody-drug conjugates (ADCs), and AI-enabled early discovery platforms. The Company currently has more than 50 early-stage innovative assets, approximately 70% of which are expected to be best-in-class, with over 30 clinical trials ongoing globally. Henlius’ core product, serplulimab (trade name: Hetronifly^® in Europe), is the world’s first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and for perioperative gastric cancer. Up to date, it has been approved in 50 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb dulpatatug (HLX22) — are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius has established a stable global supply system serving six continents. Guided by a patient-centred mission, Henlius remains focused on addressing unmet medical needs and translating scientific innovation into meaningful clinical value and patient access, contributing sustainably to the global biopharmaceutical ecosystem.

To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.